Skip to main content
. 2015 Oct;3(5 Suppl):146–687. doi: 10.1177/2050640615601623

Table 1.

Influence of ECCO Guidelines (2009) on screening for infections in patients starting biologic therapy

All, n (%) Pre ECCO, n (%) Post ECCO, n (%) p value
Hep B sAg 89 (47.6) 39 (33.9) 50 (69.4) <0.001
HepB cAb 15 (8) 10 (8.7) 5 (6.9) 0.67
HepB sAb 30 (16) 11 (9.6) 19 (26.4) 0.002
Hep C Ab 92 (49.2) 37 (32.2) 55 (76.4) <0.001
HIV Ab 79 (42.2) 27 (23.5) 52 (72.2) <0.001
TB Elispot 58 (31) 11 (9.6) 47 (65.3) <0.001
CXR 162 (86.6) 100 (87) 62 (86.1) 0.87